Helicobacter pylori eradication prevents extension of intestinalization even in the high-risk group for gastric cancer

Digestion. 2010;81(4):223-30. doi: 10.1159/000264651. Epub 2010 Jan 29.

Abstract

Background/aims: CDX2 is associated with the intestinal phenotype in the gastrointestinal tracts and is expressed in the intestinal type of gastric cancer. Helicobacter pylori-associated atrophic gastritis is characterized by aberrant expression of CDX2. The aim was to investigate the effects of eradication to the expression of genes related to the gastric and intestinal phenotype including CDX2. We compared the effect of eradication between the patients at high risk for gastric cancer and controls.

Methods: 20 patients with endoscopic resection for early gastric cancer and 12 sex- and age-matched controls were studied. CDX2 and mucin mRNA expressions were examined using whole biopsy specimens and microdissected gastric glands taken from corpus lesser and greater curves before and 1 year after eradication.

Results: CDX2 and MUC2 expressions in the cancer group were significantly higher than in the controls and were significantly decreased after eradication. MUC5AC (p = 0.01) and MUC6 (p = 0.02) expression significantly increased in the control group; the difference between the two groups became significant after eradication. CDX2 expression in the glands without goblet cells was detectable and disappeared after eradication.

Conclusion: H. pylori eradication can reverse gastric phenotype and diminish aberrant CDX2 expression in the early stage of intestinalization.

Publication types

  • Comparative Study

MeSH terms

  • Aged
  • Anti-Bacterial Agents / administration & dosage
  • Biopsy, Needle
  • CDX2 Transcription Factor
  • Case-Control Studies
  • Disease Progression
  • Female
  • Follow-Up Studies
  • Gastric Mucosa / microbiology
  • Gastric Mucosa / pathology
  • Gastric Mucosa / surgery
  • Gastroscopy / methods
  • Helicobacter Infections / complications
  • Helicobacter Infections / drug therapy*
  • Helicobacter Infections / pathology
  • Helicobacter pylori / drug effects*
  • Helicobacter pylori / isolation & purification
  • Homeodomain Proteins / genetics
  • Homeodomain Proteins / metabolism*
  • Humans
  • Immunohistochemistry
  • Male
  • Middle Aged
  • Precancerous Conditions / genetics
  • Precancerous Conditions / pathology
  • Probability
  • Proton Pump Inhibitors / administration & dosage
  • RNA, Messenger / analysis
  • Reference Values
  • Reverse Transcriptase Polymerase Chain Reaction
  • Risk Assessment
  • Statistics, Nonparametric
  • Stomach Neoplasms / pathology
  • Stomach Neoplasms / prevention & control*
  • Stomach Neoplasms / surgery
  • Trans-Activators / genetics
  • Trans-Activators / metabolism*
  • Treatment Outcome

Substances

  • Anti-Bacterial Agents
  • CDX2 Transcription Factor
  • Homeodomain Proteins
  • Proton Pump Inhibitors
  • RNA, Messenger
  • Trans-Activators